AstraZeneca

ROSY-O

NCT04421963

JCP085

ROSY-O: Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

Status:

Opening Soon

26459-200.png

III

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Any Stage

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Olaparib

PARP inhibitor (p.o.)

Treatment Arms

o Experimental: Olaparib